Be careful what you wish for. Their drug has yet to show the FDA that it really works. It was been restricted to a very small cohort, and only from a young age. This data tends to show they need ATL1102 to treat fibrous for their drug to show promise. ATL1102 still shows improvement as a mono therapy.
We dont want to be undervalued. If the trial now running just replicates the previous trial serepta will be forgotten about (thats a bit tongue in cheek).
Finance wise if those options come into the money this trial should be close to covered. Platinum have a large chunk of the company now, and will be seeing blood in the water.
Drug can be approved for sale before EMA and FDA approvals are fully given, if certain criteria are met. And rare pediatric disease is a major criteria.
- Forums
- ASX - By Stock
- PER
- Ann: Positive new DMD Combination Therapy Data in mdx mice
Ann: Positive new DMD Combination Therapy Data in mdx mice, page-9
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.0¢ |
Change
0.004(4.65%) |
Mkt cap ! $81.13M |
Open | High | Low | Value | Volume |
8.6¢ | 9.1¢ | 8.5¢ | $181.6K | 2.049M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10344 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 64275 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.085 |
2 | 155000 | 0.084 |
1 | 150000 | 0.083 |
1 | 36585 | 0.082 |
3 | 43077 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 64275 | 1 |
0.091 | 106821 | 1 |
0.092 | 50000 | 1 |
0.094 | 160000 | 1 |
0.095 | 550000 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online